Back to News
Market Impact: 0.3
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Phathom Pharmaceuticals reported third-quarter 2026 revenue growth and a second consecutive quarter of positive operating profit excluding stock-based compensation. The company said it is continuing efforts to expand access to its GERD treatment VOQUEZNA; the article provided no revenue or profit figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHAT0.55
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Norwegian shares surge 13% on earnings beat, guidance raise
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates